Abstract
Background
The coronary artery abnormalities in Kawasaki disease (KD) often cause myocardial ischemia. Previous publications have described the use of thallium 201 myocardial perfusion imaging to determine the extent of ischemia in patients with KD. The technetium perfusion agents offer better resolution and may offer additional information about ventricular function in these patients. This study was performed to evaluate myocardial perfusion in patients with KD through use of technetium 99m tetrofosmin (TF) in conjunction with dipyridamole vasodilator stress.
Methods and Results
Eighty-six patients with KD aged 11.5 ± 6.4 years and 20 age-matched control patients without heart disease were studied. Among 86 patients with KD, significant coronary artery stenosis (>75%) was observed in 20, coronary aneurysm without stenosis in 37, and no coronary lesions in 29. After administration of high-dose dipyridamole infusion (0.70 mg/kg), 74 to 370 MBq TF was injected and 148 to 740 MBq TF was injected at rest 4 hours later. Single photon emission computed tomography images were obtained more than 30 minutes after TF injection. Regional myocardial hypoperfusion was observed in 18 patients who had coronary artery stenosis of 75% or greater (sensitivity, 90%, and specificity, 100%). Two patients did not demonstrate ischemic changes in coronary artery stenosis in group I; one had good collateral flow. There were no TF injection-related complications.
Conclusions
Tetrofosmin myocardial perfusion imaging can detect regional hypoperfusion in children with KD.(J Nucl Cardiol 2002;9:632-7.)
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986;315:341–7.
Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991;324:1633–9.
Kato H, Sugimura T, Akagi T, Sato N, Hashino K, Maeno Y, et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation 1996;94:1379–855.
Kato H, Ichinose E, Kawasaki T. Myocardial infarction in Kawasaki disease: clinical analyses in 195 cases. J Pediatr 1986; 108:923–7.
Kegel SM, Dorsey TJ, Rowen M, Taylor WF. Cardiac death in mucocutaneous lymph node syndrome. Am J Cardiol 1977;40:282–66.
VanTrain KF, Berman DS, Garcia EV, Berger HJ, Sands MJ, Friedman JD, et al. Quantitative analysis of stress thallium-201 myocardial scintigrams: a multicenter trial. J Nucl Med 1986;27:17–255.
Kondo C, Hiroe M, Nakanishi T, Takao A. Detection of coronary artery stenosis in children with Kawasaki disease: usefulness of pharmacologic stress 201Tl myocardial tomography. Circulation 1989;80:615–24.
Fukuda T, Akagi T, Ishibashi M, Inoue O, Sugimura T, Kato H. Noninvasive evaluation of myocardial ischemia in Kawasaki disease: comparison between dipyridamole stress thallium imaging and exercise stress testing. Am Heart J 1998;135:482–7.
American Heart Association Committee Report. A reporting system on patients evaluated for coronary artery disease. Circulation 1975;51:7–40.
Tamaki N, Ohtani H, Yonekura Y, Nohara R, Kambara H, Kawai C, et al. Significance on fill-in after thallium-201 reinjection following delayed imaging: comparison with regional wall motion and angiographic findings. J Nucl Med 1990;31:1617–233.
Garcia EV, Train KV, Maddahi J, Prigent F, Friedman J, Areeda J, et al. Quantification of rotational thallium-201 myocardial tomography. J Nucl Med 1985;26:17–26.
Fujiwara H, Hamashima Y. Pathology of the heart in Kawasaki disease. Pediatrics 1978;61:100–7.
Sugimura T, Kato H, Inoue O, Fukuda T, Sato N, Ishii M, et al. Intravascular ultrasound of coronary arteries in children. Assessment of the wall morphology and the lumen after Kawasaki disease. Circulation 1994;89:258–65.
Berman DS. Technetium-99m myocardial perfusion imaging agents and their relations to thallium-201. Am J Cardiol 1990; 66:1E-4E.
Higley B, Smith FW, Smith T, Gemmel HG, Gupta PD, Gvozdanovic DV, Graham D, Hinge D, Davidson J, Lahiri A. Technetium-99m-1,2-bis[bis(2-ethoxyethyl)phosphino] ethane: human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent. J Nucl Med 1993;34:30–8.
Jain D, Wackers FJ Th, Mattera J, McMahon M, Sinusas AJ, Zaret BL. Biokinetics of technetium-99m-tetrofosmin: myocardial perfusion imaging agent: implications for a one-day imaging protocol. J Nucl Med 1993;34:1254–9.
Kelly JD, Forster AM, Higley B, Archer CM, Booker FS, Canning LR, et al. Technetium-99m-tetrofosmin as a new radiopharmaceutical for myocardial perfusion imaging. J Nucl Med 1993;34:222–7.
Homma S, Gilliland Y, Guiney TE, Strauss HW, Boucher CA. Safety of intravenous dipyridamole for stress testing with thallium imaging. Am J Cardiol 1987;59:152–4.
Gould KL. Noninvasive assessment of coronary stenosis by myocardial perfusion imaging during pharmacologic coronary vasodilatation. I. Physiologic basis and experimental validation. Am J Cardiol 1978;41:267–78.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fukuda, T., Ishibashi, M., Yokoyama, T. et al. Myocardial ischemia in Kawasaki disease: Evaluation with dipyridamole stress technetium 99m tetrofosmin scintigraphy. J Nucl Cardiol 9, 632–637 (2002). https://doi.org/10.1067/mnc.2002.125915
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1067/mnc.2002.125915